DURECT Corporation (NASDAQ:DRRX) was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued on Friday, Marketbeat Ratings reports.

Several other research firms also recently weighed in on DRRX. ValuEngine raised shares of DURECT Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of DURECT Corporation in a research note on Sunday, June 25th.

DURECT Corporation (DRRX) opened at 0.8914 on Friday. The company has a 50-day moving average of $1.74 and a 200-day moving average of $1.47. The firm’s market capitalization is $131.03 million. DURECT Corporation has a 52 week low of $0.74 and a 52 week high of $2.17.

DURECT Corporation (NASDAQ:DRRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. The company had revenue of $4.32 million during the quarter, compared to the consensus estimate of $5.17 million. On average, equities analysts forecast that DURECT Corporation will post ($0.21) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “DURECT Corporation (DRRX) Cut to Hold at Stifel Nicolaus” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/21/durect-corporation-drrx-cut-to-hold-at-stifel-nicolaus.html.

Large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new stake in shares of DURECT Corporation during the first quarter worth about $118,000. Voya Investment Management LLC increased its position in shares of DURECT Corporation by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after acquiring an additional 15,394 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of DURECT Corporation during the first quarter worth about $147,000. State of Wisconsin Investment Board bought a new stake in shares of DURECT Corporation during the second quarter worth about $151,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of DURECT Corporation by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock worth $189,000 after acquiring an additional 13,072 shares in the last quarter. 45.90% of the stock is owned by institutional investors.

About DURECT Corporation

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.